Journal of neurointerventional surgery · 2025
Submaximal versus aggressive angioplasty with drug-coated balloons for symptomatic intracranial arterial stenosis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Guangwen, Liu Yayue, Sun Xiaofei, Sun Yujie, Liu Peng, Zhang Xianjun, Anmu Xie, Zhang Yong
Аннотация
BACKGROUND: Drug-coated balloons (DCB) can decrease the incidence of restenosis in the treatment of intracranial atherosclerotic stenosis (ICAS). This study aimed to assess the safety and efficacy of submaximal angioplasty with DCB dilation compared with aggressive angioplasty in patients with symptomatic ICAS.
METHODS: This study prospectively and consecutively enrolled patients with symptomatic ICAS who underwent DCB angioplasty between January 2021 and December 2023. Based on the balloon size, the patients were divided into submaximal (50-80% of normal vessel diameter) or aggressive (80-100% of normal vessel diameter) angioplasty groups. The efficacy and safety of angioplasty including ischemic stroke/intracranial hemorrhage, death, arterial dissection, and follow-up outcomes were compared between the two groups.
RESULTS: The patients were divided into submaximal (n=55) and aggressive (n=62) angioplasty groups. All the balloons were successfully delivered to the lesion location and expanded. The dissection rate (3.6% vs 17.7%, P=0.018) and incidence of remedial stenting (7.3% vs 21.0%, P=0.040) after balloon dilation were significantly greater after aggressive angioplasty than after submaximal angioplasty. A residual stenosis rate of ≥30% was more common in the submaximal angioplasty group than in the aggressive angioplasty group (27.3% vs 8.1%, P=0.006). Periprocedural complications (1.8% vs 8.1%, P=0.212), recurrent ischemic events (1.8% vs 4.8%, P=0.621), and restenosis (3.6% vs 8.1%, p=0.445) were comparable between the groups.
CONCLUSIONS: Submaximal angioplasty has a favorable technical profile, periprocedural safety, and long-term efficacy, suggesting that it is a promising alternative treatment for symptomatic ICAS.
METHODS: This study prospectively and consecutively enrolled patients with symptomatic ICAS who underwent DCB angioplasty between January 2021 and December 2023. Based on the balloon size, the patients were divided into submaximal (50-80% of normal vessel diameter) or aggressive (80-100% of normal vessel diameter) angioplasty groups. The efficacy and safety of angioplasty including ischemic stroke/intracranial hemorrhage, death, arterial dissection, and follow-up outcomes were compared between the two groups.
RESULTS: The patients were divided into submaximal (n=55) and aggressive (n=62) angioplasty groups. All the balloons were successfully delivered to the lesion location and expanded. The dissection rate (3.6% vs 17.7%, P=0.018) and incidence of remedial stenting (7.3% vs 21.0%, P=0.040) after balloon dilation were significantly greater after aggressive angioplasty than after submaximal angioplasty. A residual stenosis rate of ≥30% was more common in the submaximal angioplasty group than in the aggressive angioplasty group (27.3% vs 8.1%, P=0.006). Periprocedural complications (1.8% vs 8.1%, P=0.212), recurrent ischemic events (1.8% vs 4.8%, P=0.621), and restenosis (3.6% vs 8.1%, p=0.445) were comparable between the groups.
CONCLUSIONS: Submaximal angioplasty has a favorable technical profile, periprocedural safety, and long-term efficacy, suggesting that it is a promising alternative treatment for symptomatic ICAS.